Clinical Trials Directory

Trials / Completed

CompletedNCT01065571

Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
15 (actual)
Sponsor
University of Illinois at Chicago · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study hypothesis is that withdrawal of carrageenan will lead to a longer, relapse free interval in patients with ulcerative colitis.

Detailed description

This study will evaluate the interval to relapse in patients with ulcerative colitis. The patients will be adults, who have been in remission for at least one month. They will have previously required corticosteroids to induce remission. Subjects will be instructed in a no-carrageenan diet and required to follow this diet for the duration of their participation in the clinical study. They will be randomized to receive either placebo capsules or capsules containing carrageenan 100 mg. In this way, the study will be a double blind study of no-carrageenan vs. carrageenan. Main study outcome is the interval to relapse. Since ulcerative colitis is associated with relapses, relapse is anticipated. Other outcome measures will include scores on questionnaires, including the SSCAI and the SIDBQ, and laboratory measurements of inflammation. Subjects will participate for one year or until relapse, with study visits every three months and telephone contacts every two weeks. After three months, participants will increase to two capsules daily, of either placebo or carrageenan.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTcarrageenanThe intervention is the carrageenan-free diet. Supplementary carrageenan capsules will be given to mimic the carrageenan in the normal diet.
OTHERdietary intervention with no-carrageenan dietThe intervention will consist of the no-carrageenan diet.

Timeline

Start date
2010-01-01
Primary completion
2013-12-01
Completion
2014-01-01
First posted
2010-02-09
Last updated
2019-11-26
Results posted
2019-11-26

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01065571. Inclusion in this directory is not an endorsement.